Combining Clarivate’s robust proprietary data with extensive bespoke consulting and custom research capabilities, we develop nuanced, defendable assessments and strategies to help biopharmaceutical and MedTech clients make better, more informed decisions in a rapidly changing landscape.
By harnessing deep domain knowledge, proprietary data sets, and broad methodological capabilities, we provide innovative problem-solving approaches to biopharma and Medtech’s toughest challenges. Our pioneering insight-enabled consulting model sets us apart, empowering us to focus on co-creation, thought partnership, and custom solutions.
Developing an approach that maximizes product and portfolio impact requires a detailed, nuanced understanding of disease area and industry dynamics. Backed by deep domain knowledge and extensive experience from proof of concept through lifecycle management, our team delivers strategic, data-driven recommendations to support clinical development, enable effective product positioning, and fuel successful market adoption.
Critical to the commercial success of a product is a detailed understanding of its market access potential. Our team’s extensive experience and proprietary data assets enable us to guide you through the evolving complexities of global reimbursement markets with thoughtful consideration of the unique dynamics at play.
German federal agency SPRIND turned to Clarivate for assistance in evaluating potential investments in breakthrough innovations, particularly in the field of biotech. We provided expertise in life sciences, intellectual property, and oncology, and produced comprehensive market assessment reports for key oncology indications. With our help, SPRIND was able to confidently invest in projects with high potential for improving the quality of life for people in Germany and around the world.